LOTRISONE
LOE ApproachingNDATOPICALLOTION
Approved
Dec 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 43m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOTRISONE is a topical lotion combining an antifungal and corticosteroid, approved by the FDA in December 2000 for dermatological fungal infections. The dual mechanism addresses both the fungal pathogen and associated inflammation. It is a small molecule topical combination therapy for localized skin conditions.
LOE Approaching
Product faces approaching loss of exclusivity with moderate competitive pressure (30%), signaling contraction in team size and focus shifting to retention versus growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LOTRISONE offers limited growth opportunity given its LOE-approaching lifecycle stage; roles are primarily defensive and focused on market retention and generic transition management. Career development is better served on growth-stage or early-launch products within the Merck portfolio.
Brand ManagerField Sales Representative
Worked on LOTRISONE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.